Jun Zhao
YOU?
Author Swipe
View article: A novel nomogram based on DLL3 and PD-L1 for predicting the prognosis of patients with small cell lung cancer
A novel nomogram based on DLL3 and PD-L1 for predicting the prognosis of patients with small cell lung cancer Open
The prognostic model developed in this study offers predictive value in estimating 12-month survival probability for SCLC patients, aiding clinicians in making more informed treatment decisions.
View article: Supplementary Figure S3 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
Supplementary Figure S3 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis Open
Outcomes of treatment for the patient subgroup with MET overexpression
View article: Supplementary Figure S4 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
Supplementary Figure S4 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis Open
Treatment-related adverse events in treated patients with MET amplification and/or MET IHC 2+/3+
View article: Supplementary PLS from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
Supplementary PLS from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis Open
Plain language summary
View article: Supplementary Table S1 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
Supplementary Table S1 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis Open
Demographic data of all individuals enrolled
View article: Longitudinal <i>in vivo</i> ( <i>R</i> )-[ <sup>18</sup> F]FBFP PET imaging for preclinical evaluation of cerebral sigma-1 receptor after ischemic stroke
Longitudinal <i>in vivo</i> ( <i>R</i> )-[ <sup>18</sup> F]FBFP PET imaging for preclinical evaluation of cerebral sigma-1 receptor after ischemic stroke Open
View article: Tislelizumab plus sitravatinib or anlotinib as maintenance therapy in extensive‐stage small‐cell lung cancer: Results of two prospective phase <scp>II</scp> studies
Tislelizumab plus sitravatinib or anlotinib as maintenance therapy in extensive‐stage small‐cell lung cancer: Results of two prospective phase <span>II</span> studies Open
First‐line chemo‐immunotherapy has significantly improved survival in extensive‐stage small‐cell lung cancer (ES‐SCLC). However, rapid disease progression still occurs, with a median progression‐free survival (PFS) of only 4.5–5.8 months f…
View article: Nivolumab in gastric cancer with liver metastasis complicated by immune-mediated hepatitis: a case report and FAERS database analysis
Nivolumab in gastric cancer with liver metastasis complicated by immune-mediated hepatitis: a case report and FAERS database analysis Open
Nivolumab is a monoclonal antibody that targets the PD-1 pathway, significantly transforming cancer immunotherapy. However, its use is associated with immune-related adverse events (irAEs), including immune-mediated hepatitis (IMH), which …
View article: Polyvinyl Chloride Promotes Radioresistance in Hepatocellular Carcinoma by Inhibiting Radiotherapy-Induced CD8⁺ T Cell Differentiation
Polyvinyl Chloride Promotes Radioresistance in Hepatocellular Carcinoma by Inhibiting Radiotherapy-Induced CD8⁺ T Cell Differentiation Open
Radiotherapy (RT) has emerged as one of the primary treatment modalities for intermediate and advanced hepatocellular carcinoma (HCC). However, RT resistance remains widespread. Microplastics (MPs) have been detected in various tumors and …
View article: Case Report: Multimodal management of a rare pediatric astroblastoma using proton beam therapy and Gamma Knife radiosurgery—a case report and literature review
Case Report: Multimodal management of a rare pediatric astroblastoma using proton beam therapy and Gamma Knife radiosurgery—a case report and literature review Open
Introduction Astroblastoma is an infrequent glial tumor, with the MN1-altered subtype recognized in the 2021 WHO classification. This report details the management of a 4-year-old girl diagnosed with CNS WHO Grade 3 MN1-altered astroblasto…
View article: An Open‐Label, Single‐Arm, Phase <scp>II</scp> Trial of Sintilimab Plus Anlotinib for Metastatic Non‐Small Cell Lung Cancer After First‐Line <scp>PD</scp> ‐(L)1 Inhibitor
An Open‐Label, Single‐Arm, Phase <span>II</span> Trial of Sintilimab Plus Anlotinib for Metastatic Non‐Small Cell Lung Cancer After First‐Line <span>PD</span> ‐(L)1 Inhibitor Open
Background Although immune checkpoint inhibitors (ICIs) have markedly improved first‐line management of non‐small cell lung cancer (NSCLC), many tumors eventually escape control after anti‐PD‐(L)1 therapy, leaving a clear therapeutic gap. …
View article: A prospective non-randomized interventional study of dynamic changes of L3SMI in patients with gastric cancer undergoing ambulatory chemotherapy with active nutrition combined with exercise
A prospective non-randomized interventional study of dynamic changes of L3SMI in patients with gastric cancer undergoing ambulatory chemotherapy with active nutrition combined with exercise Open
Objective To compare the effects of combined active nutrition and exercise intervention based on a standard regimen on the dynamic changes in the L3 skeletal muscle index (L3SMI) of patients with gastric cancer receiving SOX/XELOX ambulato…
View article: Efficacy and safety of first-line chemoimmunotherapy in young patients with extensive-stage small cell lung cancer: a multicenter retrospective study
Efficacy and safety of first-line chemoimmunotherapy in young patients with extensive-stage small cell lung cancer: a multicenter retrospective study Open
The young group had poorer survival outcomes and chemoimmunotherapy may not provide a survival benefit in young patients, as evidenced by similar PFS and OS compared to chemotherapy. Additionally, the young group also experienced a higher …
View article: High-Dose Aumolertinib for Untreated <i>EGFR</i>-Variant Non–Small Cell Lung Cancer With Brain Metastases
High-Dose Aumolertinib for Untreated <i>EGFR</i>-Variant Non–Small Cell Lung Cancer With Brain Metastases Open
Importance Central nervous system (CNS) metastases remain a significant challenge in the management of EGFR -variant non–small cell lung cancer (NSCLC). Objective To evaluate the activity and safety of high-dose aumolertinib in patients wi…
View article: The efficacy of platelet-rich plasma preparation protocols in the treatment of osteoarthritis: a network meta-analysis of randomized controlled trials
The efficacy of platelet-rich plasma preparation protocols in the treatment of osteoarthritis: a network meta-analysis of randomized controlled trials Open
View article: Neoadjuvant Osimertinib for Resectable <i>EGFR</i> -Mutated Non–Small Cell Lung Cancer
Neoadjuvant Osimertinib for Resectable <i>EGFR</i> -Mutated Non–Small Cell Lung Cancer Open
PURPOSE Adjuvant osimertinib is the standard of care for patients with resected epidermal growth factor receptor ( EGFR )–mutated non–small cell lung cancer (NSCLC). Neoadjuvant treatment could improve surgical and long-term outcomes. METH…
View article: Amivantamab in Participants With Advanced NSCLC and MET Exon 14 Skipping Mutations: Final Results From the CHRYSALIS Study
Amivantamab in Participants With Advanced NSCLC and MET Exon 14 Skipping Mutations: Final Results From the CHRYSALIS Study Open
The safety profile was consistent with previous reports of amivantamab in EGFR-mutant NSCLC. Amivantamab demonstrated clinically meaningful and durable antitumor activity in participants with METex14 advanced NSCLC, including those who pro…
View article: Ethylene Oxide Exposure and the Risk of Congestive Heart Failure: Evidence from NHANES 2013-2018 Data
Ethylene Oxide Exposure and the Risk of Congestive Heart Failure: Evidence from NHANES 2013-2018 Data Open
Background Ethylene oxide (EO), a pervasive industrial chemical, has been linked to carcinogenic and respiratory effects, but its cardiovascular implications remain underexplored. This study investigates the association between EO exposure…
View article: Anlotinib-associated pulmonary embolism in brainstem glioblastoma treatment: a case report
Anlotinib-associated pulmonary embolism in brainstem glioblastoma treatment: a case report Open
Background Glioblastoma (GBM) is the most common and aggressive primary brain malignancy in adults. Diagnosis primarily relies on imaging techniques like CT scan and MRI, while pathological biopsy remains the diagnostic gold standard. Stan…
View article: Efficacy and Safety of Peptide Receptor Radionuclide Therapy for the Treatment of Pancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis of Comparative Studies
Efficacy and Safety of Peptide Receptor Radionuclide Therapy for the Treatment of Pancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis of Comparative Studies Open
[This retracts the article DOI: 10.7759/cureus.80817.].
View article: Endovascular embolization of post-tonsillectomy pseudoaneurysm in adults
Endovascular embolization of post-tonsillectomy pseudoaneurysm in adults Open
Objective This study aims to evaluate the efficacy and safety of endovascular embolization in the treatment of post-tonsillectomy pseudoaneurysms. Methods We conducted a retrospective analysis of four consecutive adults who experienced sec…
View article: Comparison of the effectiveness of alectinib versus crizotinib followed by alectinib in patients with ALK-positive advanced non-small-cell lung cancer in real-world setting and in the ALEX study
Comparison of the effectiveness of alectinib versus crizotinib followed by alectinib in patients with ALK-positive advanced non-small-cell lung cancer in real-world setting and in the ALEX study Open
Our real world data suggested that sequential group was associated with a higher risk of progression in the brain than the alectinib upfront treatment. However, both treatments had similar survival in advanced ALK-positive NSCLC. Patients …
View article: Prevalence, genetic variations and clinical outcomes of BRAF-V600 mutated advanced NSCLC in China: a retrospective real-world multi-centre study
Prevalence, genetic variations and clinical outcomes of BRAF-V600 mutated advanced NSCLC in China: a retrospective real-world multi-centre study Open
National Natural Science Foundation of China (82072583); Beijing Municipal Administration of Hospitals Incubating Program (PX2020044); Beijing Hospitals Authority Youth Programme (QML20231113); Science Foundation of Peking University Cance…
View article: Association between immune-related adverse events and prognosis in immune checkpoint inhibitor therapy: A bibliometric and visual analysis
Association between immune-related adverse events and prognosis in immune checkpoint inhibitor therapy: A bibliometric and visual analysis Open
With the gradual improvement in tumor immunotherapy, the incidence of immune-related adverse events (irAEs) has increased. However, according to current research, the relationship between irAEs and prognosis remains a contentious issue. Th…
View article: Can Exercise-Mediated Adipose Browning Provide an Alternative Explanation for the Obesity Paradox?
Can Exercise-Mediated Adipose Browning Provide an Alternative Explanation for the Obesity Paradox? Open
Overweight patients with cardiovascular disease (CVD) tend to survive longer than normal-weight patients, a phenomenon known as the “obesity paradox”. The phenotypic characteristics of adipose distribution in these patients (who survive lo…
View article: Ensartinib for advanced or metastatic non-small-cell lung cancer with MET exon 14 skipping mutations (EMBRACE): a multi-center, single-arm, phase 2 trial
Ensartinib for advanced or metastatic non-small-cell lung cancer with MET exon 14 skipping mutations (EMBRACE): a multi-center, single-arm, phase 2 trial Open
View article: Aumolertinib Plus Apatinib Versus Aumolertinib in Untreated, EGFR-Mutant, Advanced NSCLC (ATTENTION): A Randomized, Multi-Center, Phase 2 Study
Aumolertinib Plus Apatinib Versus Aumolertinib in Untreated, EGFR-Mutant, Advanced NSCLC (ATTENTION): A Randomized, Multi-Center, Phase 2 Study Open
View article: Deep Learning and Radiomics in Triple-Negative Breast Cancer: Predicting Long-Term Prognosis and Clinical Outcomes
Deep Learning and Radiomics in Triple-Negative Breast Cancer: Predicting Long-Term Prognosis and Clinical Outcomes Open
Triple-negative breast cancer (TNBC) is a unique breast cancer subtype characterized by the lack of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression in tumor cells. TNBC rep…
View article: Correlation of senescence-related gene FEN1 on neuroblastoma progression and cisplatin chemotherapy sensitivity
Correlation of senescence-related gene FEN1 on neuroblastoma progression and cisplatin chemotherapy sensitivity Open
Bioinformatics and sequencing analyses indicate that the senescence-related gene FEN1 is significantly associated with cisplatin sensitivity and adverse prognosis in pediatric NB. FEN1 plays a pivotal role in regulating NB cell proliferati…
View article: Phase II Trial of Neoadjuvant Camrelizumab and Apatinib in Resectable NSCLC: 3-Year Survival Outcomes and Dynamic Circulating Tumor DNA Analyses
Phase II Trial of Neoadjuvant Camrelizumab and Apatinib in Resectable NSCLC: 3-Year Survival Outcomes and Dynamic Circulating Tumor DNA Analyses Open